Ask one question. Spotter reads the filings and answers — with citations.
Spotter reads your intent, dispatches the right agents to cross-verify 7 data sources, and reads the actual SEC & FDA filings — handing back a summary, risks, and next steps where every claim is quoted and sourced.
Every answer cites these sources — traceable to the original line. How we verify →
- 01
You ask, in plain language
One question — no filters, no dashboards to learn.
- 02
Spotter reads intent & dispatches agents
It picks the right agents to cross-verify across 7 data sources.
- 03
It reads the filings & cites every claim
SEC & FDA source text, quoted line by line.
Every conclusion below is Spotter's actual output — each claim quoted from the source, no login required.
Rocket Pharmaceuticals Inc. is a fully-integrated, late-stage biotechnology company developing gene therapies for rare, monogenic diseases, with a focus on cardiovascular indications and a recently approved product, KRESLADI™, though it has not yet generated product revenue.
- KRESLADI™ was approved by the FDA in March 2026 under the accelerated approval pathway [sec_mda · as of 2026-05-07].
- As of 2026-03-31, the company reported cash & equivalents of $51.0M, no revenue, a net loss of $47.6M, shareholders' equity of $277.2M, and total debt of $19.3M [sec].
- The company operates a ~100,000 sq. ft. in-house AAV cGMP manufacturing facility in Cranbury, New Jersey [sec · filed 2026-04-06].
- Rocket has incurred net losses of $223.1M and $258.7M for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $1.44 billion as of December 31, 2025 [sec_mda · as of 2026-02-26].
- The company's pipeline includes late-stage programs for Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301), with a Phase 2 pivotal trial design agreed with the FDA for RP-L301 [sec · filed 2025-04-30].
What works
- KRESLADI™ received FDA accelerated approval in March 2026, marking a key regulatory milestone and potential revenue source [sec_mda · as of 2026-05-07].
- The company has a fully-integrated platform with in-house AAV cGMP manufacturing capabilities, supporting clinical development and potential future commercialization [sec · filed 2026-04-06].
- Rocket's leadership team has a proven track record of over 20 successful U.S. and international drug approvals and launches, with expertise in cell and gene therapies and rare diseases [sec · filed 2026-04-06].
- The company is strategically focused on rare cardiovascular indications, targeting genetically defined causes of cardiomyopathies that impact more than 100,000 patients in the U.S. and EU [sec_mda · as of 2026-02-26].
What to weigh
- Rocket has not yet generated any revenue from product sales and has incurred net losses and negative cash flows from operations each year since inception [sec_mda · as of 2026-02-26].
- As of 2026-03-31, cash & equivalents were only $51.0M, which may limit the company's ability to fund operations and development without additional financing [sec].
- The company has an accumulated deficit of $1.44 billion as of December 31, 2025, reflecting substantial historical losses [sec_mda · as of 2026-02-26].
- Enrollment in the Phase 2 pivotal trial for RP-L301 (PKD) has not been initiated, as resources are being focused on other programs [sec · filed 2025-04-30].
From the filings
Quoted directly from source documents.
KRESLADI™ was approved by the FDA in March 2026 under accelerated approval.
“KRESLADI™ was approved by the FDA in March 2026 under the accelerated approval pathway”
SEC MD&A · May 7, 2026
The company has not generated any revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 7, 2025
Rocket has an accumulated deficit of $1.44 billion as of December 31, 2025.
“have an accumulated deficit of $1.44 billion as of December 31, 2025”
SEC MD&A · February 26, 2026
The company operates a 103,720 sq. ft. manufacturing facility in Cranbury, New Jersey.
“have a 103,720 square foot manufacturing facility located in Cranbury, New Jersey.”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2023-08-29 · Phase 1 Start: A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associate - NCT: NCT05885412 — Trial evaluating safety of RP-A601; status is recruiting.
- 2023-09-05 · Phase 2 Start: Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously - NCT: NCT06092034 — Phase 2 study for Danon Disease; status is recruiting.
- 2025-05-08 · Earnings Report - SEC 8-K filing — Quarterly earnings report.
- 2025-08-07 · Earnings Report - SEC 8-K filing — Quarterly earnings report.
- 2025-11-06 · Earnings Report - SEC 8-K filing — Quarterly earnings report.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash & equivalents of $51.0M as of 2026-03-31 may be insufficient to fund operations without additional financing [sec].
- No product revenue yet — Despite FDA approval of KRESLADI™, the company has not generated any revenue from product sales [sec_mda · as of 2026-05-07].
- Clinical development risks — Drug candidates require significant additional R&D efforts, and successful development and commercialization are highly uncertain [sec_mda · as of 2026-02-26].
- Accumulated deficit — Accumulated deficit of $1.44 billion as of December 31, 2025, reflecting substantial historical losses [sec_mda · as of 2026-02-26].
What to watch
- Commercial launch progress and revenue generation from KRESLADI™ following its March 2026 FDA approval [sec_mda · as of 2026-05-07].
- Initiation of patient enrollment in the Phase 2 pivotal trial for RP-L301 (PKD), which is currently on hold [sec · filed 2025-04-30].
- Regulatory updates on the MAA for RP-L102 (Fanconi Anemia) accepted by the EMA [sec · filed 2025-04-30].
- Cash position and any future financing activities, given the limited cash runway [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated July 20, 2026 · How we verify sources →
Backed by full-spectrum coverage
1,000+ companies, 7 authoritative sources, refreshed continuously — the ground every answer stands on.
Auto-Extract
Spotter reads SEC & FDA filings for you
Never Miss
PDUFA dates & catalyst tracking
Evidence-Based
Cross-verified with citations
7 Sources · 24/7
1,000+ companies tracked
Biotech Pulse
Live market · upcoming catalysts · curated insights — all at a glance.
XBI
$150.94-2.15%
IBB
$186.53-1.70%
New Trials Initiated
5,290
FDA Approvals
409
Partnership Deals
25,468
Phase 3 Completion
32%
Upcoming FDA Catalysts
PDUFA dates, AdCom meetings, readouts — free, no login.
Recent M&A
Start free — the full biotech intelligence stack
Create a free account to run live multi-agent analysis and track catalysts across 1,000+ biotechs.
- 200 AI credits / month
- Browse companies, pipelines, trials & catalysts
- Biotech event calendar access